Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Randomized, Open-label Study of the IGF-1R Inhibitor AXL1717 Compared to Docetaxel in Patients With Previously Treated, Locally Advanced, or Metastatic Squamous Cell Carcinoma or Adenocarcinoma of the Lung

NCT01561456 is registered in ClinicalTrials.gov with Axelar AB as lead sponsor.

NCT NCT01561456
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01561456 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Randomized, Open-label Study of the IGF-1R Inhibitor AXL1717 Compared to Docetaxel in Patients With Previously Treated, Locally Advanced, or Metastatic Squamous Cell Carcinoma or Adenocarcinoma of the Lung
Lead sponsor
Axelar AB
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2011
Completion date
December 31, 2013
Enrollment
100 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of the lung, non-small-cell lung cancer, squamous cell carcinoma